Nuvation Bio/$NUVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Employees
278
Headquarters
Website
Nuvation Bio Metrics
BasicAdvanced
$1.3B
-
-$0.63
1.35
-
Price and volume
Market cap
$1.3B
Beta
1.35
52-week high
$4.09
52-week low
$1.54
Average daily volume
7M
Financial strength
Current ratio
9.392
Quick ratio
9.259
Long term debt to equity
13.508
Total debt to equity
15.49
Interest coverage (TTM)
293.03%
Profitability
EBITDA (TTM)
201.481
Gross margin (TTM)
27.54%
Net profit margin (TTM)
-1,413.43%
Operating margin (TTM)
1,396.27%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
20.17%
Return on equity (TTM)
-44.84%
Valuation
Price to revenue (TTM)
84.742
Price to book
3.46
Price to tangible book (TTM)
3.58
Price to free cash flow (TTM)
-7.216
Free cash flow yield (TTM)
-13.86%
Free cash flow per share (TTM)
-0.522
Growth
Revenue change (TTM)
900.35%
Earnings per share change (TTM)
-72.24%
3-year earnings per share growth (CAGR)
8.80%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Bulls say / Bears say
FDA approval of Ibtrozi (taletrectinib) for ROS1-positive NSCLC transforms Nuvation Bio into a commercial-stage oncology company. (Reuters)
Ibtrozi showed strong response rates and durable clinical benefit in two Phase II trials, highlighting its efficacy and potential for differentiation in ROS1+ NSCLC. (Reuters)
RBC Capital Markets estimates Ibtrozi could see peak sales as high as $640 million by 2034, indicating meaningful long-term revenue growth potential. (Reuters)
Shares fell 17.4% to $2.09 after FDA approval, signaling investor worries about product launch execution and the details of the drug’s labeling. (Reuters)
Ibtrozi will have to compete with established ROS1 inhibitors—Bristol-Myers Squibb’s Augtyro, Pfizer’s Xalkori, and Roche’s Rozlytrek—which could make it difficult to gain significant market share. (Reuters)
With a list price of $29,488 per month, Ibtrozi could face pushback from insurers and challenges securing reimbursement, potentially affecting how widely it is adopted commercially. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Business Wire1 week ago
Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Business Wire3 weeks ago
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $1.3B as of October 07, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of October 07, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.